BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11706781)

  • 1. 3-hour infusion of single-agent paclitaxel for recurrent ovarian cancer.
    Ishikawa H; Nakanishi T; Nawa A; Suzuki Y; Kuzuya K
    Int J Clin Oncol; 2001 Jun; 6(3):128-31. PubMed ID: 11706781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paclitaxel efficacy and tolerability in second-line treatment of refractory and relapsed ovarian cancer patients.
    Oliverio G; Canuti D; Tononi A; Scarpellini M; Panzini I; Galli I; Ravaioli A
    J Chemother; 1999 Aug; 11(4):301-5. PubMed ID: 10465133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary experience with salvage weekly paclitaxel in women with advanced recurrent ovarian carcinoma.
    Dunder I; Berker B; Atabekoglu C; Bilgin T
    Eur J Gynaecol Oncol; 2005; 26(1):79-82. PubMed ID: 15755007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group.
    Ezcurdia L; Jovtis SL; Mickiewicz E; Temperley G; Rondinón M; Blajman C; Cóppola FS; Lewi D; Cazap E; Breier S; Fasce H; Fein L; Polera J; Triguboff E; Uranga G; Pasccón G; Luchina AM; Martínez CA; Politi PM; Rubio G; Alvarez AM
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-53-S15-56. PubMed ID: 9346223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic administration of single weekly paclitaxel in heavily pretreated ovarian cancer patients.
    Yamamoto K; Oogi S; Inoue H; Kudoh K; Kita T; Kikuchi Y
    Curr Med Chem; 2004 Feb; 11(4):425-8. PubMed ID: 14965223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.
    Huizing MT; van Warmerdam LJ; Rosing H; Schaefers MC; Lai A; Helmerhorst TJ; Veenhof CH; Birkhofer MJ; Rodenhuis S; Beijnen JH; ten Bokkel Huinink WW
    J Clin Oncol; 1997 May; 15(5):1953-64. PubMed ID: 9164207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer.
    Fennelly D; Aghajanian C; Shapiro F; O'Flaherty C; McKenzie M; O'Connor C; Tong W; Norton L; Spriggs D
    J Clin Oncol; 1997 Jan; 15(1):187-92. PubMed ID: 8996141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Phase II study of paclitaxel (BMS-181339) in patients with ovarian cancer by 3-hour intravenous infusion].
    Noda K; Ikeda M; Kudo R; Nishiya I; Yajima A; Tanaka K; Kodama S; Takahashi T; Tokunaga A; Satoh I; Nozawa S; Taketani Y; Terashima Y; Isonishi S; Takeda Y; Nishijima M; Kuroshima Y; Fujii S; Izumi R; Tamaya T; Mori T; Okada H; Ogita S; Ozaki M; Hatae M
    Gan To Kagaku Ryoho; 1996 Feb; 23(3):317-25. PubMed ID: 8712825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weekly 1-h paclitaxel infusion in patients with recurrent endometrial cancer: a preliminary study.
    Nishio S; Ota S; Sugiyama T; Matsuo G; Kawagoe H; Kumagai S; Ushijima K; Nishida T; Kamura T
    Int J Clin Oncol; 2003 Feb; 8(1):45-8. PubMed ID: 12601542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-line intraperitoneal cisplatin-paclitaxel and intravenous ifosfamide in Stage IIIc ovarian epithelial cancer.
    Zylberberg B; Dormont D; Madelenat P; Daraï E
    Eur J Gynaecol Oncol; 2004; 25(3):327-32. PubMed ID: 15171311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly paclitaxel/5-fluorouracil followed by platinum retreatment for patients with recurrent ovarian cancer: a single institution experience.
    Watari H; Hosaka M; Mitamura T; Moriwaki M; Ohba Y; Todo Y; Takeda M; Ebina Y; Sakuragi N
    Eur J Gynaecol Oncol; 2008; 29(6):573-7. PubMed ID: 19115681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience.
    Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-26-S15-29. PubMed ID: 9346218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended phase II study of paclitaxel as a 3-h infusion in patients with ovarian cancer previously treated with plantinum.
    du Bois A; Lück HJ; Buser K; Meerpohl HG; Sessa C; Klaassen U; Meden H; Bochtler H; Diergarten K
    Eur J Cancer; 1997 Mar; 33(3):379-84. PubMed ID: 9155520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy of advanced inoperable non-small cell lung cancer with paclitaxel: a phase II trial.
    Gatzemeier U; Heckmayer M; Neuhauss R; Schlüter I; von Pawel J; Wagner H; Dreps A
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):24-8. PubMed ID: 8643966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weekly paclitaxel in patients with CAP-resistant advanced or recurrent endometrial carcinoma: a series of four patients.
    Akizuki S; Katsumata N; Yamanaka Y; Andoh M; Fujiwara Y; Watanabe T
    Int J Clin Oncol; 2005 Aug; 10(4):272-5. PubMed ID: 16136374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical study on the efficacy of weekly paclitaxel administration for platinum-resistant epithelial ovarian carcinoma].
    Fujii K; Takano M; Okamoto S; Sasaki N; Kita T; Kikuchi Y
    Gan To Kagaku Ryoho; 2004 Dec; 31(13):2141-4. PubMed ID: 15628759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term results of paclitaxel in FIGO stage III ovarian carcinoma.
    Gallardo-Rincón D; Pérez-Landeros L; Oñate-Ocaña LF; Mohar A; Calderillo G; de la Garza J; Cabrera P; Sánchez B; Dueñas-Gonzalez A
    Anticancer Drugs; 2003 Jun; 14(5):347-52. PubMed ID: 12782940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.